Isodiol International Inc. Announces Conference Sponsorship in Brazil

VANCOUVER, British Columbia, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC: ISOLF) (Frankfurt:LB6A.F) (the “Company” or “Isodiol”) a global cannabis innovator specializing in the development of pharmaceutical and consumer products announces it is proudly sponsoring the 50th Anniversary of IV International and XXIV Brazilian Congress of ABENEPI (Brazilian Association of Neurology and Child Psychiatry and Related Profession) August 9 – 12.  The Company is sponsoring the symposium where one of the top Brazilian child neurologists will be speaking on the benefits of Cannabidiol to an audience of doctors, neurologists and psychologists. 

Marcos Agramont CEO of Isodiol stated, “As we develop our footprint in Brazil and work through the process with Anvisa, sponsoring events like this will be very important for educating the market on the benefits of our Isoderm™ product.  Over the last several months, we have been able to generate tremendous support for our products which we anticipate will continue as we move into additional countries.”

About Isodiol International Inc.

Isodiol International, Inc. is the market leader in pharmaceutical grade cannabis compounds and the industry leader in manufacturing and development of consumer products. Isodiol's nutraceutical division is the pioneer of many firsts for Hemp-derived cannabidiol (CBD), including 99% pure crystalline isolate, micro-encapsulation, and nano technology for the highest quality consumable and topical skin care products. 

Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, seeking joint ventures and acquisitions to expand its portfolio of brands and subsidiaries and will aggressively continue International expansion into Latin America, Asia and Europe.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.

CORPORATE MEDIA:
[email protected]
www.isodiol.com

Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter: @isodiol

You May Also Be Interested In

• Hilton Grand Vacations approves new $600M share repurchase plan
• Erik Prince and Swarmer Announce Formation of Vectus Air Defense Systems
• Helen Woodward Animal Center Orphan Blind Pup Has His Sight Set on Forever Home